Rubee Apis

Rubee Apis is a preclinical-stage biotechnology company focused on developing therapeutic applications for honeybee venom-derived peptides. The company's core technology centers on melittin, a potent pore-forming peptide, which they engineer into synthetic analogs to target specific pathologies while reducing systemic toxicity. Rubee Apis utilizes advanced nanoparticle delivery systems to transport these peptides directly to tumors or infected cells. Their primary research areas include oncology, where they aim to disrupt cancer cell membranes, and infectious diseases, including the treatment of multi-drug resistant bacteria and viral pathogens like HIV. The company is headquartered in St. Louis, Missouri, and leverages research originating from Washington University to advance its candidates.